11 results about "Maternal antibody" patented technology

This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind endothelin A receptor (ETAR). These ETAR antibodies, or antigen-binding fragments thereof, have a high affinity for ETAR, function to effectively block ET-1 binding to ETAR, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., in a human), and can be used to treat ETAR-associated disorders. Importantly, compared to small molecule ETAR antagonists, the antibodies of the present invention have advantages of longer serum half-life, higher target specificity, thereby limiting the risk of off-target toxicity and improving therapeutic window.

The application discloses a mucosal immunity enhanced recombinant lactobacillus expressing PEDV S1 protein and a construction method and application thereof. The mucosal immunity enhanced recombinant lactobacillus contains a recombinant lactic acid bacteria expression vector expressing the PEDV S1 protein, wherein the PEDV S1 protein is fused with an M cell targeting peptide (Col) and a dendritic cell targeting peptide (6aa) at an amino acid end, and is fused with a mucosal immunity adjuvant (LTB) at a carboxyl end; and the connection sequence of each part is Col-6aa-S1-LTB. The mucosal immunity enhanced recombinant lactobacillus constructed by the application significantly improves the mucosal immunity response efficiency (including intestinal mucus SIgA and serum IgG levels) of the PEDV S1 antigen through the synergistic effect of the targeting peptide (DC / MC targeting peptide) and the adjuvant (LTB), and can significantly induce humoral immunity, cellular immunity and mucosal immunity response of pregnant animals and produce maternal antibodies, improves the intestinal SIgA level of newborn animals, and provides an effective technical means for the prevention and treatment of PED.

The present disclosure provides anti-CD38 IgG class antibody having improved ability to be manufactured at higher yields compared to the parent antibody having the original wild type sequence. The present disclosure provides a mutated antibody light chain that reduces cleavage heterogeneity for improved production of a homogeneous population of antibody light chains.

The utility model discloses a non-specific immunoglobulin detection kit for cattle and sheep, which relates to the technical field of livestock raising and comprises a kit body, a centrifugal tube bracket, a centrifugal tube I, a Pasteur pipette and a centrifugal tube II, the centrifugal tube bracket is used for supporting the centrifugal tube I and the centrifugal tube II, and the Pasteur pipette I is used for supporting the Pasteur pipette II. The first centrifugal tube is used for containing a sodium sulfate sterile solution, the pasteur pipettes are used for sucking serum samples to be detected, the number of the pasteur pipettes is multiple, and the second centrifugal tubes are used for containing successful passive transformation serum control samples and passive transformation failure serum control samples respectively; the non-specific immunoglobulin detection kit for cattle and sheep is used for detecting non-specific immunoglobulin in serum of newborn calves and lambs, semi-quantification is carried out through turbidimetry, and the passive conversion effect of a maternal antibody of a young livestock can be evaluated.

The application provides a pig getah virus positive serum and a preparation method and application, and belongs to the technical field of animal virology. The application provides a preparation method of a pig getah virus positive serum, wherein a CDCD pig is used as a host, neutralizing antibody titer obtained through multiple immunization of high-concentration antigen is greater than or equal to 1:512; the serum does not have cytotoxicity affecting cell culture; the CDCD pig is a pig free from maternal antibody interference, which is obtained through caesarean section, isolated feeding and artificial feeding; the positive serum does not detect pig pseudorabies virus, swine fever virus, porcine circovirus type 2, pig foot-and-mouth disease virus, bovine viral diarrhea virus, porcine infectious gastroenteritis virus, porcine epidemic diarrhea virus, porcine rotavirus, porcine parvovirus, porcine Japanese encephalitis virus antibody, and has the characteristics of high titer and no cytotoxicity.

The present invention provides a humanized anti-Bb factor antibody, a composition containing the antibody, a method for producing the antibody, and a method for using the antibody, for treating complement-mediated diseases or disorders. [Solution] A humanized anti-Bb factor antibody is provided that combines only a specific heavy chain variable region (VH) and light chain variable region (VL) to bind to Bb factor with an acceptable binding affinity. The humanized anti-Bb factor antibody of this disclosure has a binding affinity of no more than twice that of the parent antibody.

The application belongs to the technical field of veterinary medicine, and particularly relates to an adenovirus vector recombinant pig acute diarrhea syndrome coronavirus vaccine. The application constructs a replication-defective adenovirus vector vaccine (rAd-SADS-S) expressing a full-length SADS-CoV S protein, realizes immune induction of high-efficiency humoral and cellular immunity, and provides passive protection for milk mice through maternal antibody transmission, and overcomes the defects of no available vaccine for SADS-CoV, low protection rate in existing research, and biological safety risk.

The invention belongs to the technical field of veterinary medicine, and particularly relates to an adenovirus vector recombinant porcine acute diarrhea syndrome coronavirus vaccine. According to the invention, by constructing a replication-deficient adenovirus vector vaccine (rAd-SADS-S) expressing the full length of SADS-CoV S protein, efficient body fluid and cell immunity is induced by immunity, passive protection is provided for suckling mice through maternal antibody transfer, and the defects that no SADS-CoV vaccine is available and the existing research protection rate is low and the biological safety risk is caused are overcome.

This application provides isolated antibodies, and antigen-binding fragments thereof that specifically bind chemokine receptor 4 (CXCR4). These CXCR4 antibodies, or antigen-binding fragments thereof, have a high affinity for CXCR4, function to effectively block SDF-1 binding to CXCR4, thereby inhibiting forskolin stimulated cAMP with low nM IC50, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., in a human), and can be used to treat CXCR4-associated disorders while avoiding the adverse side effects associated with the current CXCR4 antagonist therapies.

The invention belongs to the technical field of biology, and discloses an influenza HA protein recombinant turkey herpesvirus strain, the preservation number of the recombinant turkey herpesvirus strain is CGMCC No.46642, and the recombinant turkey herpesvirus strain is preserved in China General Microbiological Culture Collection Center; the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation date is July 23, 2025. The recombinant turkey herpesvirus has the characteristics that: 1, the recombinant turkey herpesvirus has good safety and immunogenicity, can induce strong body fluid and cellular immune response, can realize early immunization through intraembryonic or 1-day-old inoculation, and reduces interference of maternal antibodies; and 2, the HA gene of the H7 subtype AIV and the virus HA gene of the H5 subtype AIV are inserted into the virus strain, the two genes are independently screened by the applicant, and after being loaded on an HVT vector, the HA gene and the virus HA gene can show relatively comprehensive protection aiming at the corresponding subtype. Meanwhile, the invention also provides application and a vaccine of the recombinant herpesvirus of turkeys.

The invention discloses a lactation promoting traditional Chinese medicine for promoting lactation of lactating sows and a preparation method and application thereof.The lactation promoting traditional Chinese medicine is prepared from cowherb seeds, uniflower swisscentaury roots, liquidambar formosana hance, verbena officinalis, angelica sinensis, leonurus japonicus, astragalus membranaceus and liquorice according to a specific proportion, and the raw materials are subjected to water extraction and concentration and then mixed with cyclodextrin to be prepared into granules. The lactagogue traditional Chinese medicine can significantly improve the lactation yield of lactating sows and the maternal antibody level in milk, especially the IgG and IgM content, and can improve the plasma immune globulin and prolactin level, thereby effectively promoting the growth of piglets and reducing the diarrhea rate.